This study aimed to evaluate the effect of ixekizumab on self‐reported functioning and health in patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA). COAST‐X was a controlled trial conducted randomly in nr‐axSpA patients for the course of 52‐weeks. Participants were randomized to receive placebo or subcutaneous 80 mg ixekizumab every two weeks (Q2W) or every four weeks (Q4W) for 52 Weeks.
Health endpoints and self‐reported functioning involved the European Quality of Life‐5 Dimensions‐5 Level (EQ‐5D‐5L), Assessment of SpondyloArthritis international Society Health Index (ASAS HI), Medical Outcomes Study 36‐Item, and Short-Form Health Survey 36‐item (SF‐36) health‐utility. A higher proportion of patients receiving ixekizumab reported ASAS HI improvements greater than or equal to three from the baseline at the weeks 16 (Q2W) and 52. Significantly more patients on ixekizumab reported improvements in ASAS HI “good health status” (ASAS HI ≤5) at Weeks 16 (Q4W) and 52. Patients treated by ixekizumab reported significant improvements in EQ‐5D‐5L versus placebo at week 16 (0.11 vs. 0.17 Q4W, 0.19 Q2W), which remained consistent 52. No clinically significant differences were observed in the responses based on ixekizumab dosing regimen (Q4W or Q2W).
In conclusion, Ixekizumab was found to be superior in comparison to placebo, thus improving health and self‐reported functioning in patients with nr‐axSpA at weeks 16 and 52.
Ref: https://onlinelibrary.wiley.com/doi/10.1002/acr.24482
